<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01397409</url>
  </required_header>
  <id_info>
    <org_study_id>150998-001</org_study_id>
    <secondary_id>2011-002526-43</secondary_id>
    <secondary_id>REACH Study</secondary_id>
    <nct_id>NCT01397409</nct_id>
  </id_info>
  <brief_title>Evaluation of AGN-150998 in Exudative Age-related Macular Degeneration (AMD)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is conducted in 3 stages. Stage 1 is an open-label, dose-escalation assessment of
      the safety of AGN-150998 administered as a single intravitreal injection to patients with
      advanced exudative Age-related Macular Degeneration (AMD). Stage 2 and Stage 3 are
      randomized, double-masked, comparisons of the safety and treatment effects on retinal edema
      and best-corrected visual acuity (BCVA) of AGN-150998 and ranibizumab in treatment-naive
      patients with exudative AMD. Study medication is administered as needed in Stage 2 and with a
      fixed-dosing schedule in Stage 3. The study objectives are (1) to identify the highest
      tolerated dose of AGN-150998, (2) to assess the safety and duration of treatment effects on
      retinal edema and BCVA, and (3) to characterize the systemic pharmacokinetic profile of
      AGN-150998.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Highest Tolerated Dose (HTD) of AGN-150998</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Stage 1 evaluated the safety of a single intravitreal injection of AGN-150998 with doses ranging from 1.0 to 4.2 mg.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stage 1: Change From Baseline in Central Retinal Thickness (CRT) in the Study Eye</measure>
    <time_frame>Baseline, Week 4</time_frame>
    <description>CRT was assessed using spectral domain optical coherence tomography (SD-OCT), a non-invasive diagnostic system providing high-resolution imaging sections of the retina. SD-OCT was performed in the study eye after pupil dilation. A negative change from Baseline indicated improvement.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stage 2: Time Between Baseline Treatment and Recurrence of Active Disease</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <description>Recurrence of Active Disease was based on Best Corrected Visual Acuity (BCVA), Central Retinal Thickness (CRT) values as evaluated by the Central Reading Center (CRC) and the investigator assessments of haemorrhage.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stage 3: Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <description>BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stage 2: Time Between Second Treatment and Recurrence of Active Disease</measure>
    <time_frame>32 Weeks</time_frame>
    <description>Recurrence of active disease is defined as the time in days to escape to standard of care. Time is calculated as (date of Escaping to Standard of Care/Censoring minus the date of the Second Injection) +1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 2: Change From Baseline in Central Retinal Thickness (CRT) in the Study Eye</measure>
    <time_frame>Baseline, Week 4</time_frame>
    <description>CRT was assessed using spectral domain optical coherence tomography (SD-OCT), a non-invasive diagnostic system providing high-resolution imaging sections of the retina. SD-OCT was performed in the study eye after pupil dilation. A negative change from Baseline indicated improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 2: Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye</measure>
    <time_frame>Baseline, Week 4</time_frame>
    <description>BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 3: Change From Baseline in Central Retinal Thickness (CRT) in the Study Eye</measure>
    <time_frame>Baseline, Week 4</time_frame>
    <description>CRT was assessed using spectral domain optical coherence tomography (SD-OCT), a non-invasive diagnostic system providing high-resolution imaging sections of the retina. SD-OCT was performed in the study eye after pupil dilation. A negative change from Baseline indicated improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 3: Change From Baseline in BCVA in the Study Eye</measure>
    <time_frame>Baseline, Week 4</time_frame>
    <description>BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved.</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">271</enrollment>
  <condition>Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Stage 1: AGN-150998 4.2 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stage 1: AGN-150998 4.2.mg given as a single intravitreal injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1: AGN-150998 3.0 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stage 1: AGN-150998 3.0 mg given as a single intravitreal injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1: AGN-150998 2.0 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stage 1: AGN-150998 2.0 mg given as a single intravitreal injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1: AGN-150998 1.0 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stage 1: AGN-150998 1.0 mg given as a single intravitreal injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2: AGN-150998 4.2 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stage 2: AGN-150998 4,2 mg (highest tolerated dose from Stage 1) given as a single intravitreal injection at baseline. A second intravitreal injection will be given by week 16.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2: AGN-150998 3.0 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stage 2: AGN-150998 3.0 mg (one dose below highest tolerated dose) from Stage 1 given as a single intravitreal injection at baseline. A second intravitreal injection will be given by week 16.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2: ranibizumab 0.5 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Stage 2: ranibizumab 0.5 mg given as a single intravitreal injection at baseline. A second intravitreal injection will be given by week 16.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 3: AGN-150998 2.0 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stage 3: AGN-150998 2.0 mg given as intravitreal injections at Baseline, Weeks 4 and 8, followed by sham injections at Weeks 12 and 16.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 3: AGN-150998 1.0 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stage 3: AGN-150998 1.0 mg given as intravitreal injections at Baseline, Weeks 4 and 8, followed by sham injections at Weeks 12 and 16.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 3: ranibizumab 0.5 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Stage 3: ranibizumab 0.5 mg given as intravitreal injections every 4 weeks for 16 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AGN-150998</intervention_name>
    <description>AGN-150998 Intravitreal injection.</description>
    <arm_group_label>Stage 1: AGN-150998 4.2 mg</arm_group_label>
    <arm_group_label>Stage 1: AGN-150998 3.0 mg</arm_group_label>
    <arm_group_label>Stage 1: AGN-150998 2.0 mg</arm_group_label>
    <arm_group_label>Stage 1: AGN-150998 1.0 mg</arm_group_label>
    <arm_group_label>Stage 2: AGN-150998 4.2 mg</arm_group_label>
    <arm_group_label>Stage 2: AGN-150998 3.0 mg</arm_group_label>
    <arm_group_label>Stage 3: AGN-150998 2.0 mg</arm_group_label>
    <arm_group_label>Stage 3: AGN-150998 1.0 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ranibizumab</intervention_name>
    <description>Ranibizumab 0.5 mg given by intravitreal injection.</description>
    <arm_group_label>Stage 2: ranibizumab 0.5 mg</arm_group_label>
    <arm_group_label>Stage 3: ranibizumab 0.5 mg</arm_group_label>
    <other_name>Lucentis®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham Injection</intervention_name>
    <description>Stage 3: Sham injection at Weeks 12 and 16.</description>
    <arm_group_label>Stage 3: AGN-150998 2.0 mg</arm_group_label>
    <arm_group_label>Stage 3: AGN-150998 1.0 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Exudative age-related macular degeneration

          -  Best-corrected visual acuity between 20/32 and 20/320 in the study eye

        Exclusion Criteria:

          -  Near-sightedness of 8 diopters or more

          -  Uncontrolled glaucoma in the study eye

          -  Cataract surgery or Lasik within the last 3 months

          -  Any active ocular infection or inflammation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Binningen</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2011</study_first_submitted>
  <study_first_submitted_qc>July 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2011</study_first_posted>
  <results_first_submitted>June 2, 2015</results_first_submitted>
  <results_first_submitted_qc>June 2, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 18, 2015</results_first_posted>
  <last_update_submitted>June 2, 2015</last_update_submitted>
  <last_update_submitted_qc>June 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Stage 1: AGN-150998 4.2 mg</title>
          <description>Stage 1: AGN-150998 4.2 mg given as a single intravitreal injection.</description>
        </group>
        <group group_id="P2">
          <title>Stage 1: AGN-150998 3.0 mg</title>
          <description>Stage 1: AGN-150998 3.0 mg given as a single intravitreal injection.</description>
        </group>
        <group group_id="P3">
          <title>Stage 1: AGN-150998 2.0 mg</title>
          <description>Stage 1: AGN-150998 2.0 mg given as a single intravitreal injection</description>
        </group>
        <group group_id="P4">
          <title>Stage 1: AGN-150998 1.0 mg</title>
          <description>Stage 1: AGN-150998 1.0 mg given as a single intravitreal injection.</description>
        </group>
        <group group_id="P5">
          <title>Stage 2: AGN-150998 4.2 mg</title>
          <description>Stage 2: AGN-150998 4.2 mg (highest tolerated dose from Stage 1) given as a single intravitreal injection at baseline. A second intravitreal injection will be given by week 16.</description>
        </group>
        <group group_id="P6">
          <title>Stage 2: AGN-150998 3.0 mg</title>
          <description>Stage 2: AGN-150998 3.0 mg (one dose below highest tolerated dose from Stage 1) given as a single intravitreal injection at baseline. A second intravitreal injection will be given by week 16.</description>
        </group>
        <group group_id="P7">
          <title>Stage 2: Ranibizumab 0.5 mg</title>
          <description>Stage 2: ranibizumab 0.5 mg given as a single intravitreal injection at baseline. A second intravitreal injection will be given by week 16.</description>
        </group>
        <group group_id="P8">
          <title>Stage 3: AGN-150998 2.0 mg</title>
          <description>Stage 3: AGN-150998 2.0 mg given as intravitreal injections at Baseline, Weeks 4 and 8, followed by sham injections at Weeks 12 and 16.</description>
        </group>
        <group group_id="P9">
          <title>Stage 3: AGN-150998 1.0 mg</title>
          <description>Stage 3: AGN-150998 1.0 mg given as intravitreal injections at Baseline, Weeks 4 and 8, followed by sham injections at Weeks 12 and 16.</description>
        </group>
        <group group_id="P10">
          <title>Stage 3: Ranibizumab 0.5 mg</title>
          <description>Stage 3: ranibizumab 0.5 mg given as intravitreal injections every 4 weeks for 16 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Stage 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Stage 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="67"/>
                <participants group_id="P6" count="58"/>
                <participants group_id="P7" count="58"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="59"/>
                <participants group_id="P6" count="54"/>
                <participants group_id="P7" count="58"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Personal Reasons</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Miscellaneous Reasons</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Stage 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="23"/>
                <participants group_id="P9" count="25"/>
                <participants group_id="P10" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="21"/>
                <participants group_id="P9" count="25"/>
                <participants group_id="P10" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Miscellaneous Reasons</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Stage 1: AGN-150998 4.2 mg</title>
          <description>Stage 1: AGN-150998 4.2 mg given as a single intravitreal injection.</description>
        </group>
        <group group_id="B2">
          <title>Stage 1: AGN-150998 3.0 mg</title>
          <description>Stage 1: AGN-150998 3.0 mg given as a single intravitreal injection.</description>
        </group>
        <group group_id="B3">
          <title>Stage 1: AGN-150998 2.0 mg</title>
          <description>Stage 1: AGN-150998 2.0 mg given as a single intravitreal injection</description>
        </group>
        <group group_id="B4">
          <title>Stage 1: AGN-150998 1.0 mg</title>
          <description>Stage 1: AGN-150998 1.0 mg given as a single intravitreal injection.</description>
        </group>
        <group group_id="B5">
          <title>Stage 2: AGN-150998 4.2 mg</title>
          <description>Stage 2: AGN-150998 4.2 mg (highest tolerated dose from Stage 1) given as a single intravitreal injection at baseline. A second intravitreal injection will be given by week 16.</description>
        </group>
        <group group_id="B6">
          <title>Stage 2: AGN-150998 3.0 mg</title>
          <description>Stage 2: AGN-150998 3.0 mg (one dose below highest tolerated dose from Stage 1) given as a single intravitreal injection at baseline. A second intravitreal injection will be given by week 16.</description>
        </group>
        <group group_id="B7">
          <title>Stage 2: Ranibizumab 0.5 mg</title>
          <description>Stage 2: ranibizumab 0.5 mg given as a single intravitreal injection at baseline. A second intravitreal injection will be given by week 16.</description>
        </group>
        <group group_id="B8">
          <title>Stage 3: AGN-150998 2.0 mg</title>
          <description>Stage 3: AGN-150998 2.0 mg given as intravitreal injections at Baseline, Weeks 4 and 8, followed by sham injections at Weeks 12 and 16.</description>
        </group>
        <group group_id="B9">
          <title>Stage 3: AGN-150998 1.0 mg</title>
          <description>Stage 3: AGN-150998 1.0 mg given as intravitreal injections at Baseline, Weeks 4 and 8, followed by sham injections at Weeks 12 and 16.</description>
        </group>
        <group group_id="B10">
          <title>Stage 3: Ranibizumab 0.5 mg</title>
          <description>Stage 3: ranibizumab 0.5 mg given as intravitreal injections every 4 weeks for 16 weeks</description>
        </group>
        <group group_id="B11">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="3"/>
            <count group_id="B5" value="67"/>
            <count group_id="B6" value="58"/>
            <count group_id="B7" value="58"/>
            <count group_id="B8" value="23"/>
            <count group_id="B9" value="25"/>
            <count group_id="B10" value="16"/>
            <count group_id="B11" value="271"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82.3" lower_limit="68" upper_limit="89"/>
                    <measurement group_id="B2" value="75.3" lower_limit="62" upper_limit="86"/>
                    <measurement group_id="B3" value="79.3" lower_limit="72" upper_limit="91"/>
                    <measurement group_id="B4" value="67.7" lower_limit="64" upper_limit="71"/>
                    <measurement group_id="B5" value="80.4" lower_limit="58" upper_limit="95"/>
                    <measurement group_id="B6" value="78.6" lower_limit="63" upper_limit="94"/>
                    <measurement group_id="B7" value="78.5" lower_limit="59" upper_limit="92"/>
                    <measurement group_id="B8" value="77.9" lower_limit="67" upper_limit="89"/>
                    <measurement group_id="B9" value="75.5" lower_limit="54" upper_limit="91"/>
                    <measurement group_id="B10" value="76.5" lower_limit="53" upper_limit="86"/>
                    <measurement group_id="B11" value="77.2" lower_limit="53" upper_limit="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="34"/>
                    <measurement group_id="B6" value="35"/>
                    <measurement group_id="B7" value="38"/>
                    <measurement group_id="B8" value="13"/>
                    <measurement group_id="B9" value="18"/>
                    <measurement group_id="B10" value="8"/>
                    <measurement group_id="B11" value="159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="33"/>
                    <measurement group_id="B6" value="23"/>
                    <measurement group_id="B7" value="20"/>
                    <measurement group_id="B8" value="10"/>
                    <measurement group_id="B9" value="7"/>
                    <measurement group_id="B10" value="8"/>
                    <measurement group_id="B11" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Highest Tolerated Dose (HTD) of AGN-150998</title>
        <description>Stage 1 evaluated the safety of a single intravitreal injection of AGN-150998 with doses ranging from 1.0 to 4.2 mg.</description>
        <time_frame>24 Weeks</time_frame>
        <population>Safety population included all treated participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage 1 All Participants</title>
            <description>Participants in Stage 1 received an intravitreal injection of AGN-150998 with doses ranging from 1.0 to 4.2 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Highest Tolerated Dose (HTD) of AGN-150998</title>
          <description>Stage 1 evaluated the safety of a single intravitreal injection of AGN-150998 with doses ranging from 1.0 to 4.2 mg.</description>
          <population>Safety population included all treated participants.</population>
          <units>mg</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Stage 1: Change From Baseline in Central Retinal Thickness (CRT) in the Study Eye</title>
        <description>CRT was assessed using spectral domain optical coherence tomography (SD-OCT), a non-invasive diagnostic system providing high-resolution imaging sections of the retina. SD-OCT was performed in the study eye after pupil dilation. A negative change from Baseline indicated improvement.</description>
        <time_frame>Baseline, Week 4</time_frame>
        <population>Safety population included all treated participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage 1: AGN-150998 4.2 mg</title>
            <description>Stage 1: AGN-150998 4.2 mg given as a single intravitreal injection.</description>
          </group>
          <group group_id="O2">
            <title>Stage 1: AGN-150998 3.0 mg</title>
            <description>Stage 1: AGN-150998 3.0 mg given as a single intravitreal injection</description>
          </group>
          <group group_id="O3">
            <title>Stage 1: AGN-150998 2.0 mg</title>
            <description>Stage 1: AGN-150998 2.0 mg given as a single intravitreal injection.</description>
          </group>
          <group group_id="O4">
            <title>Stage 1: AGN-150998 1.0 mg</title>
            <description>Stage 1: AGN-150998 1.0 mg given as a single intravitreal injection</description>
          </group>
        </group_list>
        <measure>
          <title>Stage 1: Change From Baseline in Central Retinal Thickness (CRT) in the Study Eye</title>
          <description>CRT was assessed using spectral domain optical coherence tomography (SD-OCT), a non-invasive diagnostic system providing high-resolution imaging sections of the retina. SD-OCT was performed in the study eye after pupil dilation. A negative change from Baseline indicated improvement.</description>
          <population>Safety population included all treated participants.</population>
          <units>microns</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="527.6" spread="126.79"/>
                    <measurement group_id="O2" value="540.3" spread="284.34"/>
                    <measurement group_id="O3" value="500.3" spread="155.65"/>
                    <measurement group_id="O4" value="564.3" spread="115.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 4 (n=9,6,6,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-185.4" spread="161.23"/>
                    <measurement group_id="O2" value="-239.5" spread="234.03"/>
                    <measurement group_id="O3" value="-212.3" spread="182.94"/>
                    <measurement group_id="O4" value="-113.5" spread="135.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Stage 2: Time Between Baseline Treatment and Recurrence of Active Disease</title>
        <description>Recurrence of Active Disease was based on Best Corrected Visual Acuity (BCVA), Central Retinal Thickness (CRT) values as evaluated by the Central Reading Center (CRC) and the investigator assessments of haemorrhage.</description>
        <time_frame>Baseline, Week 16</time_frame>
        <population>Per-protocol Population included all treated participants who received all scheduled treatments.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage 2: AGN-150998 4.2 mg</title>
            <description>Stage 2: AGN-150998 4.2 mg (highest tolerated dose from Stage 1) given as a single intravitreal injection at baseline. A second intravitreal injection will be given by week 16.</description>
          </group>
          <group group_id="O2">
            <title>Stage 2: AGN-150998 3.0 mg</title>
            <description>Stage 2: AGN-150998 3.0 mg (one dose below highest tolerated dose from Stage 1) given as a single intravitreal injection at baseline. A second intravitreal injection will be given by week 16.</description>
          </group>
          <group group_id="O3">
            <title>Stage 2: Ranibizumab 0.5 mg</title>
            <description>Stage 2: ranibizumab 0.5 mg given as a single intravitreal injection at baseline. A second intravitreal injection will be given by week 16.</description>
          </group>
        </group_list>
        <measure>
          <title>Stage 2: Time Between Baseline Treatment and Recurrence of Active Disease</title>
          <description>Recurrence of Active Disease was based on Best Corrected Visual Acuity (BCVA), Central Retinal Thickness (CRT) values as evaluated by the Central Reading Center (CRC) and the investigator assessments of haemorrhage.</description>
          <population>Per-protocol Population included all treated participants who received all scheduled treatments.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.0" lower_limit="43.0" upper_limit="109.0"/>
                    <measurement group_id="O2" value="57.0" lower_limit="43.0" upper_limit="86.0"/>
                    <measurement group_id="O3" value="57.0" lower_limit="43.0" upper_limit="85.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Stage 3: Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye</title>
        <description>BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved.</description>
        <time_frame>Baseline, Week 16</time_frame>
        <population>Modified-Intent-to-Treat (mITT) Population</population>
        <group_list>
          <group group_id="O1">
            <title>Stage 3: AGN-150998 2.0 mg</title>
            <description>Stage 3: AGN-150998 2.0 mg given as intravitreal injections at Baseline, Weeks 4 and 8, followed by sham injections at Weeks 12 and 16.</description>
          </group>
          <group group_id="O2">
            <title>Stage 3: AGN-150998 1.0 mg</title>
            <description>Stage 3: AGN-150998 1.0 mg given as intravitreal injections at Baseline, Weeks 4 and 8, followed by sham injections at Weeks 12 and 16</description>
          </group>
          <group group_id="O3">
            <title>Stage 3: Ranibizumab 0.5 mg</title>
            <description>Stage 3: ranibizumab 0.5 mg given as intravitreal injections every 4 weeks for 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Stage 3: Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye</title>
          <description>BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved.</description>
          <population>Modified-Intent-to-Treat (mITT) Population</population>
          <units>letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.5" spread="14.29"/>
                    <measurement group_id="O2" value="58.4" spread="13.49"/>
                    <measurement group_id="O3" value="60.4" spread="16.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" spread="7.89"/>
                    <measurement group_id="O2" value="6.3" spread="7.81"/>
                    <measurement group_id="O3" value="5.3" spread="11.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stage 2: Time Between Second Treatment and Recurrence of Active Disease</title>
        <description>Recurrence of active disease is defined as the time in days to escape to standard of care. Time is calculated as (date of Escaping to Standard of Care/Censoring minus the date of the Second Injection) +1.</description>
        <time_frame>32 Weeks</time_frame>
        <population>mITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Stage 2: AGN-150998 4.2 mg</title>
            <description>Stage 2: AGN-150998 4.2 mg (highest tolerated dose from Stage 1) given as a single intravitreal injection at baseline. A second intravitreal injection will be given by week 16.</description>
          </group>
          <group group_id="O2">
            <title>Stage 2: AGN-150998 3.0 mg</title>
            <description>Stage 2: AGN-150998 3.0 mg (one dose below highest tolerated dose from Stage 1) given as a single intravitreal injection at baseline. A second intravitreal injection will be given by week 16.</description>
          </group>
          <group group_id="O3">
            <title>Stage 2: Ranibizumab 0.5 mg</title>
            <description>Stage 2: ranibizumab 0.5 mg given as a single intravitreal injection at baseline. A second intravitreal injection will be given by week 16.</description>
          </group>
        </group_list>
        <measure>
          <title>Stage 2: Time Between Second Treatment and Recurrence of Active Disease</title>
          <description>Recurrence of active disease is defined as the time in days to escape to standard of care. Time is calculated as (date of Escaping to Standard of Care/Censoring minus the date of the Second Injection) +1.</description>
          <population>mITT Population</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.0" lower_limit="57.0" upper_limit="118.0"/>
                    <measurement group_id="O2" value="112.0" lower_limit="60.0">75% Upper Limit not estimated.</measurement>
                    <measurement group_id="O3" value="111.0" lower_limit="57.0">75% Upper Limit not estimated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stage 2: Change From Baseline in Central Retinal Thickness (CRT) in the Study Eye</title>
        <description>CRT was assessed using spectral domain optical coherence tomography (SD-OCT), a non-invasive diagnostic system providing high-resolution imaging sections of the retina. SD-OCT was performed in the study eye after pupil dilation. A negative change from Baseline indicated improvement.</description>
        <time_frame>Baseline, Week 4</time_frame>
        <population>Per-protocol Population included all treated participants who received all scheduled treatments.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage 2: AGN-150998 4.2 mg</title>
            <description>Stage 2: AGN-150998 4.2 mg (highest tolerated dose from Stage 1) given as a single intravitreal injection at baseline. A second intravitreal injection will be given by week 16.</description>
          </group>
          <group group_id="O2">
            <title>Stage 2: AGN-150998 3.0 mg</title>
            <description>Stage 2: AGN-150998 3.0 mg (one dose below highest tolerated dose from Stage 1) given as a single intravitreal injection at baseline. A second intravitreal injection will be given by week 16.</description>
          </group>
          <group group_id="O3">
            <title>Stage 2: Ranibizumab 0.5 mg</title>
            <description>Stage 2: ranibizumab 0.5 mg given as a single intravitreal injection at baseline. A second intravitreal injection will be given by week 16.</description>
          </group>
        </group_list>
        <measure>
          <title>Stage 2: Change From Baseline in Central Retinal Thickness (CRT) in the Study Eye</title>
          <description>CRT was assessed using spectral domain optical coherence tomography (SD-OCT), a non-invasive diagnostic system providing high-resolution imaging sections of the retina. SD-OCT was performed in the study eye after pupil dilation. A negative change from Baseline indicated improvement.</description>
          <population>Per-protocol Population included all treated participants who received all scheduled treatments.</population>
          <units>microns</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="524.6" spread="170.71"/>
                    <measurement group_id="O2" value="507.3" spread="139.88"/>
                    <measurement group_id="O3" value="497.1" spread="122.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 4 (n=61,56,57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-179.5" spread="123.76"/>
                    <measurement group_id="O2" value="-155.3" spread="109.13"/>
                    <measurement group_id="O3" value="-157.3" spread="121.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stage 2: Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye</title>
        <description>BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved.</description>
        <time_frame>Baseline, Week 4</time_frame>
        <population>Per-protocol Population included all treated participants who received all scheduled treatments.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage 2: AGN-150998 4.2 mg</title>
            <description>Stage 2: AGN-150998 4.2 mg (highest tolerated dose from Stage 1) given as a single intravitreal injection at baseline. A second intravitreal injection will be given by week 16.</description>
          </group>
          <group group_id="O2">
            <title>Stage 2: AGN-150998 3.0 mg</title>
            <description>Stage 2: AGN-150998 3.0 mg (one dose below highest tolerated dose from Stage 1) given as a single intravitreal injection at baseline. A second intravitreal injection will be given by week 16.</description>
          </group>
          <group group_id="O3">
            <title>Stage 2: Ranibizumab 0.5 mg</title>
            <description>Stage 2: ranibizumab 0.5 mg given as a single intravitreal injection at baseline. A second intravitreal injection will be given by week 16.</description>
          </group>
        </group_list>
        <measure>
          <title>Stage 2: Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye</title>
          <description>BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved.</description>
          <population>Per-protocol Population included all treated participants who received all scheduled treatments.</population>
          <units>letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.5" spread="13.90"/>
                    <measurement group_id="O2" value="52.7" spread="12.62"/>
                    <measurement group_id="O3" value="55.4" spread="13.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 4 (n=62,56,57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="9.71"/>
                    <measurement group_id="O2" value="8.4" spread="11.51"/>
                    <measurement group_id="O3" value="5.9" spread="64.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stage 3: Change From Baseline in Central Retinal Thickness (CRT) in the Study Eye</title>
        <description>CRT was assessed using spectral domain optical coherence tomography (SD-OCT), a non-invasive diagnostic system providing high-resolution imaging sections of the retina. SD-OCT was performed in the study eye after pupil dilation. A negative change from Baseline indicated improvement.</description>
        <time_frame>Baseline, Week 4</time_frame>
        <population>Per-protocol Population included all treated participants who received all scheduled treatments.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage 3: AGN-150998 2.0 mg</title>
            <description>Stage 3: AGN-150998 2.0 mg given as intravitreal injections at Baseline, Weeks 4 and 8, followed by sham injections at Weeks 12 and 16.</description>
          </group>
          <group group_id="O2">
            <title>Stage 3: AGN-150998 1.0 mg</title>
            <description>Stage 3: AGN-150998 1.0 mg given as intravitreal injections at Baseline, Weeks 4 and 8, followed by sham injections at Weeks 12 and 16</description>
          </group>
          <group group_id="O3">
            <title>Stage 3: Ranibizumab 0.5 mg</title>
            <description>Stage 3: ranibizumab 0.5 mg given as intravitreal injections every 4 weeks for 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Stage 3: Change From Baseline in Central Retinal Thickness (CRT) in the Study Eye</title>
          <description>CRT was assessed using spectral domain optical coherence tomography (SD-OCT), a non-invasive diagnostic system providing high-resolution imaging sections of the retina. SD-OCT was performed in the study eye after pupil dilation. A negative change from Baseline indicated improvement.</description>
          <population>Per-protocol Population included all treated participants who received all scheduled treatments.</population>
          <units>microns</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="466.0" spread="125.96"/>
                    <measurement group_id="O2" value="526.1" spread="165.09"/>
                    <measurement group_id="O3" value="463.3" spread="94.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-119.8" spread="68.50"/>
                    <measurement group_id="O2" value="-168.3" spread="137.07"/>
                    <measurement group_id="O3" value="-98.4" spread="65.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stage 3: Change From Baseline in BCVA in the Study Eye</title>
        <description>BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved.</description>
        <time_frame>Baseline, Week 4</time_frame>
        <population>Per-protocol Population included all treated participants who received all scheduled treatments.</population>
        <group_list>
          <group group_id="O1">
            <title>Stage 3: AGN-150998 2.0 mg</title>
            <description>Stage 3: AGN-150998 2.0 mg given as intravitreal injections at Baseline, Weeks 4 and 8, followed by sham injections at Weeks 12 and 16.</description>
          </group>
          <group group_id="O2">
            <title>Stage 3: AGN-150998 1.0 mg</title>
            <description>Stage 3: AGN-150998 1.0 mg given as intravitreal injections at Baseline, Weeks 4 and 8, followed by sham injections at Weeks 12 and 16</description>
          </group>
          <group group_id="O3">
            <title>Stage 3: Ranibizumab 0.5 mg</title>
            <description>Stage 3: ranibizumab 0.5 mg given as intravitreal injections every 4 weeks for 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Stage 3: Change From Baseline in BCVA in the Study Eye</title>
          <description>BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved.</description>
          <population>Per-protocol Population included all treated participants who received all scheduled treatments.</population>
          <units>letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.5" spread="14.29"/>
                    <measurement group_id="O2" value="58.4" spread="13.49"/>
                    <measurement group_id="O3" value="60.4" spread="16.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="7.40"/>
                    <measurement group_id="O2" value="4.6" spread="5.98"/>
                    <measurement group_id="O3" value="3.9" spread="6.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Stage 1: AGN-150998 4.2 mg</title>
          <description>Stage 1: AGN-150998 4.2 mg given as a single intravitreal injection.</description>
        </group>
        <group group_id="E2">
          <title>Stage 1: AGN-150998 3.0 mg</title>
          <description>Stage 1: AGN-150998 3.0 mg given as a single intravitreal injection.</description>
        </group>
        <group group_id="E3">
          <title>Stage 1: AGN-150998 2.0 mg</title>
          <description>Stage 1: AGN-150998 2.0 mg given as a single intravitreal injection</description>
        </group>
        <group group_id="E4">
          <title>Stage 1: AGN-150998 1.0 mg</title>
          <description>Stage 1: AGN-150998 1.0 mg given as a single intravitreal injection.</description>
        </group>
        <group group_id="E5">
          <title>Stage 2: AGN-150998 4.2 mg</title>
          <description>Stage 2: AGN-150998 4.2 mg (highest tolerated dose from Stage 1) given as a single intravitreal injection at baseline. A second intravitreal injection will be given by week 16.</description>
        </group>
        <group group_id="E6">
          <title>Stage 2: AGN-150998 3.0 mg</title>
          <description>Stage 2: AGN-150998 3.0 mg (one dose below highest tolerated dose from Stage 1) given as a single intravitreal injection at baseline. A second intravitreal injection will be given by week 16.</description>
        </group>
        <group group_id="E7">
          <title>Stage 2: Ranibizumab 0.5 mg</title>
          <description>Stage 2: ranibizumab 0.5 mg given as a single intravitreal injection at baseline. A second intravitreal injection will be given by week 16.</description>
        </group>
        <group group_id="E8">
          <title>Stage 3: AGN-150998 2.0 mg</title>
          <description>Stage 3: AGN-150998 2.0 mg given as intravitreal injections at Baseline, Weeks 4 and 8, followed by sham injections at Weeks 12 and 16.</description>
        </group>
        <group group_id="E9">
          <title>Stage 3: AGN-150998 1.0 mg</title>
          <description>Stage 3: AGN-150998 1.0 mg given as intravitreal injections at Baseline, Weeks 4 and 8, followed by sham injections at Weeks 12 and 16.</description>
        </group>
        <group group_id="E10">
          <title>Stage 3: Ranibizumab 0.5 mg</title>
          <description>Stage 3: ranibizumab 0.5 mg given as intravitreal injections every 4 weeks for 16 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="58"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="58"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Uveitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Anterior chamber inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Vitritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Choroiditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Optic ischaemic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Retinal artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Endophthalmitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Atypical pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Rectal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Temporal arteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="51" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="35" subjects_at_risk="58"/>
                <counts group_id="E7" subjects_affected="35" subjects_at_risk="58"/>
                <counts group_id="E8" subjects_affected="10" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="15" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="9" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Anterior chamber inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Retinal pigment epithelial tear</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="58"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Eye irritation</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Anterior chamber cell</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Anterior chamber flare</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Hyalosis asteroid</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Macular oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Foreign body sensation in eyes</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Retinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Vitreous detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="58"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Vitritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Vitreous floaters</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Age-related macular degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Macular scar</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Choroidal neovascularisation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Ocular discomfort</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Laceration</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory tract congestion</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Urticaria</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head,</name_or_title>
      <organization>Allergan, Inc</organization>
      <phone>714-246-4500</phone>
      <email>clinicaltrials@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

